---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-138272"
form_type: "8-K"
ticker: null
cik: "0001796129"
company_name: "Vincerx Pharma, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T01:05:55.873923+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vincerx Pharma Q1 2024 net loss $12.4M ($0.58/sh); cash $5.1M plus $17.8M financing through 2024

## Summary
- Cash $5.1M at Mar 31, 2024; April financing of ~$17.8M extends runway through 2024.
- Net loss $12.4M ($0.58/sh) vs $14.6M ($0.69/sh) in Q1 2023; R&D spend $4.6M down from $10.9M.
- VIP943 Phase 1 in fourth cohort; no dose-limiting toxicities in 11 pts; preliminary PK shows minimal circulating payload.
- Enitociclib NIH combo study: four PRs in PTCL and one PR in tFL monotherapy; 63 pts enrolled overall.
- VIP236 Phase 1 signs of tumor reduction and improved safety profile; updated data expected by end of Q3 2024.

## SEC filing metadata
- accession: 0001193125-24-138272
- form_type: 8-K
- cik: 0001796129
- company_name: Vincerx Pharma, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1796129/000119312524138272/0001193125-24-138272-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1796129/000119312524138272/d825581d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-138272
- JSON: https://secwatch.observer/filing/0001193125-24-138272.json
- Plain text: https://secwatch.observer/filing/0001193125-24-138272.txt

## Key facts
- Earnings Releases
  Vincerx Pharma, Inc. reported financial results for first quarter of 2024.
  - Period: first quarter of 2024
  - Result: reported results
  source text: On May 14, 2024, Vincerx Pharma, Inc. (the “Company”) issued a press release announcing financial results for its fiscal quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1796129/000119312524138272/0001193125-24-138272-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.